Pegasys

Syscoin Launches the Public Testnet for Rollux, a First-of-its-Kind Rollup Solution Offering Unprecedented Security, Speed and Scale

Retrieved on: 
Wednesday, September 28, 2022
Blockchain, Software, Networks, Internet, Cryptocurrency, Professional Services, Technology, Security, DeNet, Token, Pegasys, Prisoner of war, Cross, BAIF Development Research Foundation, EVM, Poda, Solution, Foundation, Optimism, Web3, Cryptocurrency, Ethereum, Bitcoin

Rolluxs ultimate security, throughput, and low cost make it the premier Layer 2 solution for Web3 projects.

Key Points: 
  • Rolluxs ultimate security, throughput, and low cost make it the premier Layer 2 solution for Web3 projects.
  • As rollups emerge it is important to remember that the best scalability isnt just about meeting needs with speed and low fees.
  • Security and decentralization are also key to properly supporting high value use cases, said Jag Sidhu, Syscoin Lead Developer and Foundation President.
  • Although proto-danksharding is estimated to be about a year away, PoDA is currently operational and available for evaluation on Syscoins public testnet.

Luxy NFT Marketplace: Now Live on Syscoin

Retrieved on: 
Thursday, July 14, 2022
Goal, Blockchain, Marketing, Optimism, Non-fungible token, Launch pad, Polygon, Metaverse, Collection, Organization, Mining, NFT, Ecosystem, API, DEX, Industry, APY, Cryptocurrency, Video game console, Ethereum, Bitcoin, Pegasys

The SysPunks NFT collection will go live as the first official Syscoin NFT collection on the marketplace within just a few hours of Luxy going live on Syscoin.

Key Points: 
  • The SysPunks NFT collection will go live as the first official Syscoin NFT collection on the marketplace within just a few hours of Luxy going live on Syscoin.
  • $LUXY holders are now bridging their LUXY tokens from the Polygon Network to Syscoin via Multichain.org , which supports bridging $LUXY between BNB Chain, Polygon and Syscoin.
  • Luxy will also launch their own multichain Luxy NFT Launchpad for organizations, artists and creators.
  • The grand debut of Luxys NFT Launchpad will feature a countdown timer to the release of a highly anticipated NFT collection called LUXY Genesis.

Pegasys’ Native Token, Staking And Yield Farming Major Upgrades - Syscoin

Retrieved on: 
Monday, June 6, 2022
Annual percentage rate, DEX, Time, TVL, APY, GLOBE, APR, UI, DAO, AMM, Cryptocurrency, Pegasys, Ethereum, Bitcoin

Eindhoven, Netherlands, June 06, 2022 (GLOBE NEWSWIRE) -- Pegasys, the first and leading AMM on Syscoins NEVM, released major upgrades at the end of April: their native token, PSYS, staking, and yield farming.

Key Points: 
  • Eindhoven, Netherlands, June 06, 2022 (GLOBE NEWSWIRE) -- Pegasys, the first and leading AMM on Syscoins NEVM, released major upgrades at the end of April: their native token, PSYS, staking, and yield farming.
  • Pegasys farms present an excellent opportunity for Syscoin ecosystem users to lock their assets in a liquidity pool and earn an attractive APY (Annual Percentage Yield) on their funds.
  • The time is now to buy and sell tokens, provide liquidity to earn fees, and also earn PSYS by locking and staking your liquidity.
  • Pegasys inherits the interoperability of the Syscoin NEVM, which makes it an ideal DEX for trading ERC-20 tokens.

Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland

Retrieved on: 
Wednesday, April 13, 2022
Pegasys, COVID-19, PD-L1, HCV, Hepatitis B virus, HIV/AIDS, Patient, Distribution, Cornerstone, Danoprevir, Infection, THR, FASN, National Medical Products Administration, Gannex, Health, Hepatitis C, GBM, HKEX, Insurance, RNA, Occupational Safety and Health Act 1994, PBC, Hong Kong Stock Exchange, Medication, Shanghai Stock Exchange, CEO, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, NASH, R, OBI Pharma, Inc., Degenerative disease, United Kingdom, CHB, Acne, RNA polymerase II, Chinese Communist Party Committee Secretary, Ritonavir, AIDS, Ravidasvir, FXR, Generic drug, Vaccine, Pharmaceutical industry, Cancer

HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland.

Key Points: 
  • HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ --Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavir tablets in Chinese mainland.
  • Ascletis Pharmaceuticals is a wholly-owned subsidiary of Ascletis, and China Meheco International Co., Ltd. is a wholly-owned subsidiary of China Meheco Group Co., Ltd. ("China Meheco").
  • By this opportunity, we hope to explore various levels of cooperation with biotech companies in China such as Ascletis.
  • Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, said, "It's a great honor to cooperate with China Meheco in commercialization of ritonavir tablets.

Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022

Retrieved on: 
Sunday, March 27, 2022
Pegasys, Company, Cornerstone, Hepatitis B virus, Syngenic, Metabolism, Center for Drug Evaluation and Research, Mass flow (life sciences), CHB, National Medical Products Administration, Acne, Compliance, GBM, AACR, Gannex, Research, Mab, CEO, RNA, Food, NMPA, PD-1, RNA polymerase II, PBC, FXR, NASH, Center, HIV/AIDS, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, FASN, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNL, Hepatitis C, Degenerative disease, THR, R, De novo, CDE, FDA, Bevacizumab, PD-L1, Patient, Phase, Hong Kong Stock Exchange, Pharmaceutical industry, Vaccine, Cancer

Preclinical studies showed that ASC61 demonstrated significant antitumor efficacies and were well-tolerated in both syngeneic and humanized tumor mouse models.

Key Points: 
  • Preclinical studies showed that ASC61 demonstrated significant antitumor efficacies and were well-tolerated in both syngeneic and humanized tumor mouse models.
  • ASC61 was found to have favorably comparable antitumor activities as the U.S. Food and Drug Administration (FDA) approved PD-L1 therapeutic monoclonal antibody (mAb), Atezolizumab.
  • ASC60 can disrupt metabolism and tumor-associated signal transduction in tumor cells through inhibition of de novo lipogenesis (DNL).
  • Preclinical studies showed that ASC60 could suppress tumor growth and enhance the antitumor activities of mPD-1 antibody in tumor mouse models.

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries

Retrieved on: 
Tuesday, March 1, 2022
HIV/AIDS, Hepatitis B virus, Ritonavir, Hepatitis C, Hong Kong Stock Exchange, RNA, GBM, National Medical Products Administration, Cornerstone, Pegasys, FXR, THR, COVID-19, HKEX, CHB, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, PBC, Tablet, PD-L1, FASN, AbbVie, Cancer, Acne, R, Patient, Gannex, NASH, RNA polymerase II, Degenerative disease, Animal, Pharmaceutical industry, Vaccine

HANGZHOU, China and SHAOXING, China, March 1, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in eight additional European countries (Spain, Portugal, Italy, Belgium, Poland, Sweden, the Netherlands and Denmark) through its agent in Europe.

Key Points: 
  • In addition to the above eight European countries, Ascletis had submitted ritonavir marketing authorization applications in Germany, France, Ireland and United Kingdom.
  • It is expected that more marketing authorization applications for ritonavir in other regions, including Euro-Asia, North & South America, Africa and Asian Pacific, will soon be submitted by Ascletis.
  • Ascletis continues the engagement with both domestic and major multi-national pharmaceutical companies, for the commercial supplies of ritonavir within China and globally.
  • Ascletis aims to be one of the global commercial suppliers of oral ritonavir tablets.

Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries

Retrieved on: 
Sunday, February 13, 2022
Tablet, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, Pegasys, Patient, Cancer, National Medical Products Administration, Ritonavir, RNA polymerase II, FXR, Cornerstone, RNA, PD-L1, R, HKEX, OBI Pharma, Inc., FASN, Hepatitis B virus, NASH, Acne, THR, AbbVie, Solubility, Degenerative disease, CHB, PBC, Hepatitis C, GBM, HIV/AIDS, COVID-19, Gannex, Hong Kong Stock Exchange, Pharmaceutical industry, Vaccine

It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted.

Key Points: 
  • It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted.
  • Ascletis aims to be one of the global commercial suppliers of oral ritonavir tablets.
  • Ascletis owns the only authorized oral ritonavir tablet in China, which passed bioequivalence study.
  • Ascletis' oral ritonavir tablet was approved in September 2021 by China National Medical Products Administration (H20213698).

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

Retrieved on: 
Sunday, February 6, 2022
RNA, Hong Kong Stock Exchange, Gannex, Acne, CHB, HIV/AIDS, Injection, Hepatitis, HKEX, III, FXR, Degenerative disease, NASH, PD-1, Cancer, IND, GBM, Clinical trial, PD-L1, Hepatitis B virus, FDA, Patient, Food and Drug Administration, RNA polymerase II, Investigational New Drug, Safety, Ira Pastan, Bevacizumab, Hepatitis C, Cornerstone, Mass flow (life sciences), R, Pegasys, CEO, PBC, Tablet, THR, Food, FASN, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, COVID-19, Pharmaceutical industry, Vaccine

This is Ascletis' second U.S. IND approval in 2022 after ASC22 (Envafolimab) U.S. IND approval for functional cure of chronic hepatitis B (CHB).

Key Points: 
  • This is Ascletis' second U.S. IND approval in 2022 after ASC22 (Envafolimab) U.S. IND approval for functional cure of chronic hepatitis B (CHB).
  • The ASC61 Phase I trial in the U.S. is a dose escalation study in patients with advanced solid tumors.
  • The objectives of such study are to find a recommended Phase II dose (RP2D) and obtain preliminary efficacy in patients with advanced solid tumors.
  • ASC61 is an oral potent and highly selective PD-L1 small molecule inhibitor and blocks PD-1/PD-L1 interaction through inducing PD-L1 dimerization and internalization.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022
Research, Gannex, Liver cancer, HKEX, Cornerstone, Acne, CHB, Investigational New Drug, Prevalence, PD-1, RNA, COVID-19, GBM, Safety, Hong Kong Stock Exchange, NASH, Hepatitis B, Nas, CDC classification system for HIV infection, Hepatitis C, WHO, OBI Pharma, Inc., FXR, Doctor of Philosophy, HBsAg, Food, World Health Organization, Phase, Interim, FDA, Patient, Institute of Liver and Biliary Sciences, World, Association, HBV, IIB, DHHS, American Association, Pegasys, R, American Association for Cancer Research, AASLD, RNA polymerase II, CEO, Degenerative disease, IND, Hepatitis B virus, HIV/AIDS, FASN, PBC, Food and Drug Administration, PD-L1, THR, United States Department of Health and Human Services, Vaccine, Pharmaceutical industry, Medical device, Cancer

HANGZHOU and SHAOXING, China, Jan. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B (CHB).

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022
Research, Gannex, Liver cancer, HKEX, Cornerstone, Acne, CHB, Investigational New Drug, Prevalence, PD-1, RNA, COVID-19, GBM, Safety, Hong Kong Stock Exchange, NASH, Nas, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, Hepatitis C, WHO, OBI Pharma, Inc., FXR, Doctor of Philosophy, HBsAg, Food, World Health Organization, Interim, FDA, Patient, Institute of Liver and Biliary Sciences, World, Association, HBV, IIB, DHHS, American Association, Pegasys, R, American Association for Cancer Research, AASLD, RNA polymerase II, CEO, Degenerative disease, IND, Hepatitis B virus, HIV/AIDS, FASN, PBC, Food and Drug Administration, PD-L1, THR, United States Department of Health and Human Services, Pharmaceutical industry, Vaccine, Medical device, Cancer

Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.